T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$7.49B |
| 2 |
Micron Technology
MU
|
+$6.62B |
| 3 |
Lam Research
LRCX
|
+$3.45B |
| 4 |
Applied Materials
AMAT
|
+$3.03B |
| 5 |
Advanced Micro Devices
AMD
|
+$2.91B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$12.1B |
| 2 |
Apple
AAPL
|
+$11.6B |
| 3 |
Amazon
AMZN
|
+$3.54B |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$3.07B |
| 5 |
Keysight
KEYS
|
+$1.82B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 37.73% |
| 2 | Healthcare | 11.3% |
| 3 | Financials | 10.32% |
| 4 | Communication Services | 9.66% |
| 5 | Industrials | 9.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3051
Scilex Holding
SCLX
$36.6M
| $164K | ﹤0.01% |
+20,920
| New | +$153K |
|
3052
Tredegar Corp
TG
$269M
| $164K | ﹤0.01% |
20,482
+3,271
| +19% | +$27.8K |
|
|
KWY
3053
Kingsway Corp
KWY
$279M
| $163K | ﹤0.01% |
15,605
+880
| +6% | +$9.49K |
|
3054
Liberty Latin America Class A
LILA
$1.69B
| $162K | ﹤0.01% |
20,645
-9,744
| -32% | -$54.3K |
|
3055
Vera Bradley
VRA
$87.6M
| $160K | ﹤0.01% |
40,996
+9,522
| +30% | +$35.2K |
|
3056
American Resources Corp
AREC
$247M
| $159K | ﹤0.01% |
+73,800
| New | +$165K |
|
3057
Limoneira
LMNR
$271M
| $159K | ﹤0.01% |
12,078
+488
| +4% | +$6.29K |
|
3058
US Gold Corp
USAU
$260M
| $159K | ﹤0.01% |
+10,348
| New | +$164K |
|
3059
Precision BioSciences
DTIL
$200M
| $157K | ﹤0.01% |
+19,963
| New | +$140K |
|
3060
Vipshop
VIPS
$5.95B
| $157K | ﹤0.01% |
11,800
| – | – |
|
3061
KORU Medical Systems
KRMD
$145M
| $156K | ﹤0.01% |
36,991
+9,955
| +37% | +$40.8K |
|
3062
Minerva Neurosciences
NERV
$197M
| $155K | ﹤0.01% |
+27,921
| New | +$151K |
|
|
SEVN
3063
Seven Hills Realty Trust
SEVN
$167M
| $155K | ﹤0.01% |
18,344
+4,572
| +33% | +$38.2K |
|
3064
Outset Medical
OM
$62.2M
| $154K | ﹤0.01% |
35,622
-3,805
| -10% | -$16.6K |
|
3065
Coherus Oncology
CHRS
$204M
| $153K | ﹤0.01% |
108,750
+37,214
| +52% | +$60.8K |
|
3066
InfuSystem Holdings
INFU
$243M
| $153K | ﹤0.01% |
+15,816
| New | +$150K |
|
3067
Codexis
CDXS
$157M
| $152K | ﹤0.01% |
66,924
+3,331
| +5% | +$8.29K |
|
3068
Spok Holdings
SPOK
$221M
| $152K | ﹤0.01% |
14,791
| – | – |
|
3069
AlTi Global
ALTI
$373M
| $151K | ﹤0.01% |
41,752
+13,879
| +50% | +$48K |
|
3070
Invivyd
IVVD
$235M
| $151K | ﹤0.01% |
+172,695
| New | +$216K |
|
3071
Bain Capital Specialty
BCSF
$749M
| $150K | ﹤0.01% |
11,948
-667
| -5% | -$8.7K |
|
3072
FS KKR Capital
FSK
$3.31B
| $150K | ﹤0.01% |
14,273
-14,084
| -50% | -$151K |
|
3073
Sky Harbour Group
SKYH
$408M
| $150K | ﹤0.01% |
15,220
| – | – |
|
|
AIRJ
3074
Montana Technologies Corp
AIRJ
$324M
| $149K | ﹤0.01% |
26,738
+15,867
| +146% | +$61.5K |
|
3075
Acacia Research
ACTG
$445M
| $148K | ﹤0.01% |
31,709
+1,772
| +6% | +$8.51K |
|
Similar funds
T. Rowe Price Associates's Q2 2026 Portfolio in Review
As of Q2 2026, T. Rowe Price Associates held 3,356 positions worth $999B, up 16% from $865B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q2 2026 filing shows 224 new, 2,237 increased, 645 reduced and 116 closed positions. Its largest new stake was SpaceX: 10,709,016 shares worth $1.83B. The largest sale was Microsoft, an estimated $12.1B.
By sector, the portfolio is most concentrated in Technology at 38% of assets, up from 34% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2026 buy was SpaceX: 10,709,016 shares worth $1.83B.
- T. Rowe Price Associates added most to Alphabet (Google) Class A in Q2 2026, an estimated $7.49B increase.
- T. Rowe Price Associates's biggest Q2 2026 reduction was Microsoft, cutting an estimated $12.1B.
- T. Rowe Price Associates fully exited Sibanye-Stillwater in Q2 2026, selling an estimated $40.4M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $999B portfolio in Q2 2026.
- T. Rowe Price Associates opened 224 new positions and closed 116 in Q2 2026.
- T. Rowe Price Associates's portfolio value rose 16% quarter-over-quarter to $999B.
Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.